MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploi...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
التنسيق: مقال
اللغة:English
منشور في: Elsevier 2023-10-01
سلاسل:Cell Reports
الموضوعات:
CP: Cancer
CP: Metabolism
الوصول للمادة أونلاين:http://www.sciencedirect.com/science/article/pii/S2211124723012330

مواد مشابهة

مواد مشابهة